Device Trial Radar · NCT03101501
A Prospective Study To Evaluate The Raindrop Near Vision Inlay In Presybopic or Pseudophakic Patients Treated With Mitomycin C Following Femtosecond Flap Creation.
Last checked: Nov 19, 2026Latest source record: Aug 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
9
Actual
Start
Feb 14, 2017
Primary completion
Feb 1, 2018
Study completion Feb 1, 2018
Sponsor
- Lead sponsor
- Key-Whitman Eye CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 5, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 41 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The clinical objective of this study is to evaluate the Raindrop® Near Vision Inlay for the improvement of near vision in presbyopic or pseudophakic patients treated with low dose Mitomycin C immediately following femtosecond flap creation.
Conditions
- Presbyopia
Interventions
Mitomycin cDrug
Low dose mitomycin C at a concentration of 0.02% will be applied a duration of 10 to 30 seconds at the time of the surgical procedure.
Raindrop Near Vision InlayDevice
Implanted to improve near vision in Presbyopic or Pseudophakic subjects.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Uncorrected Visual AcuityTime frame: 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Chu Vision Institue
Bloomington, Minnesota
Key-Whitman Eye Center
Dallas, Texas
Parkhurst NuVision
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.